Epidemiology of thrombotic-hemostatic factors and their associations with cardiovascular disease

American Journal of Clinical Nutrition

Volumn 65, Issue 5 SUPPL., 1997, Pages

  Pearson, Thomas A ^a   LaCava, James ^b   Weil, Henry F C ^b  

^a UNIVERSITY OF ROCHESTER   (United States)

^b NONE

Author keywords

Atherosclerosis; cardiovascular disease; coagulation factors; coronary artery disease; diet; fibrinogen; fibrinolytic factors; lipoprotein(a); risk; thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; FIBRINOGEN; FIBRINOLYTIC FACTOR; LIPOPROTEIN A; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DIET; FIBRINOLYSIS; HEMOSTASIS; HUMAN; THROMBOCYTE AGGREGATION; THROMBOSIS;

EID: 0030944355     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/65.5.1674S     Document Type: Conference Paper

References (104)

1. Loscalzo J. The relation between atherosclerosis and thrombosis. Circulation 1992:86(6 suppl):III-95-9.
2. Haust MD, Wyllie JC, More RH. Atherogenesis and plasma constituents: I. Demonstration of fibrin in the white plaque by fluorescent antibody technique. Am J Pathol 1964;44:255-67.
3. Haust MD, Wyllie JC, More RH. Electron microscopy of fibrin in human atherosclerotic lesions: II. Immunohistochemical and morphological identification. Exp Mol Pathol 1965;4:206-16.
4. Carstairs KC. The identification of platelets and platelet antigens in histological sections. J Pathol Bacteriol 1965;90:225-31.
5. Blumgard HL, Schlesinger MJ, Davis D. Studies on the relation of the clinical manifestations of angina pectoris, coronary thrombosis, and myocardial infarction of the pathological findings. Am Heart J 1940;19:1-91.
6. Miller RD, Burchell HB, Edwards JE. Myocardial infarction with and without acute coronary occlusion: a pathologic study. Arch Intern Med 1951;88:597-604.
7. Branwood AW, Montgomery GL. Observations on the morbid anatomy of coronary artery disease. Scott Med J 1956;1:367-75.
8. Meade TW. Thrombosis and ischemic heart disease. Br Heart J 1985;53:473-6.
9. Dewood MA, Spores J, Notske R, et al. Prevalence of total coronary artery occlusion during the early hours and transmural myocardial infarction. N Engl J Med 1980;303:897-902.
10. Fulton WFM, Sumner DJ. Causal role of coronary thrombotic occlusion and myocardial infarction. Am J Cardiol 1977;39:327-33.
11. Mizuno K, Satomura K, Miyamoto A, et al. Angioscopic evaluation of coronary artery thrombi in acute coronary syndromes. N Engl J Med 1992;326:287-91.
12. Fibrinolytic Trialists' Collaborative (FTT) Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity events from the randomized trials of more than 1000 patients. Lancet 1994;343:311-22.
13. Anonymous. Secondary prevention of vascular disease by prolonged antiplatelet treatment: Antiplatelet Trialists' Collaboration. Br Med J (Clin Res Ed) 1988;296:320-31.
14. SALT Collaborative Group. Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischemic events. Lancet 1991;338:1345-9.
15. Yusuf S, Lessem J, Jha P, Lonn E. Primary and secondary prevention of myocardial infarction and stroke: an update of randomly allocated, controlled trials. J Hypertens 1993:11(suppl 4):S61-73.
16. Chalmers TC, Malta RJ, Smith H Jr, Kunzler AM. Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. N Engl J Med 1977;297:1091-6.
17. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990;323:147-52.
18. Sixty Plus Reinfarction Study Research Group. A double blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980;2:989-94.
19. Fuster V, Badimon L, Badimon JJ, Chesbro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:242-50.
20. Susser M. Causal thinking in the health sciences. New York: Oxford University Press, 1973:140-62.
21. Marckmann P, Sandstrom B, Jespersen J. The variability of and associations between measures of blood coagulants, fibrinolysis, and blood lipids. Atherosclerosis 1992;96:235-44.
22. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995;332:635-41.
23. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417-24.
24. Alexander RW. Inflammation and coronary artery disease. N Engl J Med 1994;331:468-9.
25. Salomaa V, Stinson V, Kark JD. Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities Study. Circulation 1995;91:284-90.
26. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994;343:940-3.
27. Hoffman C, Shah A, Sodums M, Hultin MB. Factor VII activity state in coronary artery disease. J Lab Clin Med 1988;111:475-81.
28. Miller GJ, Walter SG, Stirling Y. Assay of factor VII activity by two techniques: evidence for increased conversion of VII to alpha VIIa in hyperlipidemia, with possible implications for ischemic heart disease. Br J Haematol 1985;59:249-58.
29. Rosenson RS, Tangney CC, Hafner JM, et al. Intraindividual variability of fibrinogen levels and cardiovascular risk profile. Arterioscler Thromb 1994;14:1928-32.
30. Vernon SA, Sarembock IJ, Ayers CR, Powers ER, Gimple LW. Lipoprotein (a) assayed from frozen serum degrades with time in storage. J Am Coll Cardiol 1995;25:76A (abstr).
31. Thompson SG. Sources of variability in coagulation factor assays. Thromb Haemost 1987;58:1073-7.
32. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993;119:956-63.
33. Eliasson M. The epidemiology of fibrinogen and fibrinolysis. Determinants of plasma fibrinogen levels and fibrinolytic variables in the population of Northern Sweden. Medical dissertation. Umea University, Luleå, Sweden, 1995.
34. Folsom AR, Qamhieh HT, Flack JM, et al. Plasma fibrinogen: levels and correlates in young adults. The Coronary Artery Risk Development in Young Adults (CARDIA) Study. Am J Epidemiol 1993;138:1023-36.
35. Humphries SE, Cook M, Dubowitz M, Stirling Y, Meade TW. Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet 1987;1:1452-5.
36. Hamsten A, Iselius L, de Faire U, Blomback M. Genetic and cultural inheritance of plasma fibrinogen concentrations. Lancet 1987;2:988-91.
37. Fowkes FGR, Connor JM, Smith FB. Fibrinogen genotype and risk of peripheral vascular atherosclerosis. Lancet 1992;339:693-6.
38. Meade TW, Mellows S, Brozovic M, et al. Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986;2:533-7.
39. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984;311:501-5.
40. Stone MC, Thorp JM. Plasma fibrinogen - a major coronary risk factor. J R Coll Gen Pract 1985;35:565-9.
41. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987;258:1183-6.
42. Yarnell JW, Baker IA, Sweetnam PM. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. Circulation 1991;83:836-44.
43. Balleisen L, Schulte H, Assmann G, Epping PH, van de Loo J. Coagulation factors and the progress of coronary heart disease. Lancet 1987;2:461 (letter).
44. Cremer P, Nagel D, Bottcher B, Seidel D. Fibrinogen: ein koroner riskofactor. (Fibrinogen: a coronary risk factor.) Diagn Laborator 1992;42:28-35.
45. Balleisen L, Assmann G, Bailey J, et al. Epidemiological study on factor VII, factor VIII. and fibrinogen in an industrial population: II. Baseline data on the relation to blood pressure, blood glucose, uric acid, and lipid fractions. Thromb Haemost 1985;54:721-3.
46. Iso H, Folsom AR, Wu KK, et al. Hemostatic variables in Japanese and Caucasian men. Am J Epidemiol 1989;130:925-34.
47. Heller RF, Meade TW, Harnes AP, et al. Inter-relationships between factor VII, serum testosterone, and plasma lipoproteins. Thromb Res 1982;28:423-5.
48. Mitropoulos KA, Miller GJ, Reaves BEA, et al. Factor VII coagulant activity is strongly associated with the plasma concentration of large lipoprotein particles in middle-aged men. Atherosclerosis 1989;76:203-8.
49. Bonithan-Kopp C, Scarabin P-Y, Bara L, et al. Relationship between sex hormones and haemostatic factors in healthy middle-aged men. Atherosclerosis 1988;71:71-6.
50. Skartlien AH, Lyberg-Beckmann S, Holme I, Hjermann I, Prydz H. Effect of alteration in triglyceride levels in factor VII-phospholipid complexes in plasma. Arteriosclerosis 1989;9:798-801.
51. Hoffman CJ, Miller RH, Hultin MB. Correlation of factor VII activity and antigen with cholesterol and triglycerides in healthy young adults. Atheroscler Thromb 1992;12:267-70.
52. Yang X-C, Jing T-Y, Resnick LM, Phillips GB. Relation of hemostatic risk factors to other risk factors for coronary heart disease and to sex hormones in men. Arterioscler Thromb 1993;13:467-71.
53. Korsan-Bengtsen K, Wilhemsen C, Tibblin G. Blood coagulation and fibrinolysis in a random sample of 788 men 54 years old: II. Relations of the variables to "risk factors" for myocardial infarction. Thromb Diath Haemorrh 1972;28:89-108.
54. Ceriello A, Giugliano D, Quatrero A, Dello Russo P, Torella R. Blood glucose may condition factor VII levels in diabetic and normal subjects. Diabetologia 1988;31:889-91.
55. Folsom AR, Wu KK, Davis CE, et al. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 1991;91:191-205.
56. Brozovic M, Stirling Y, Harricks C, et al. Factor VII in an industrial population. Br J Haematol 1974;28:381-91.
57. Kario K, Matsuo T, Nakao K. Factor VII hyperactivity in the elderly. Thromb Haemost 1990;65:25-7.
58. Scarabin PY, Bonithon-Kopp C, Bara L, et al. Factor VII activation and menopausal status. Thromb Res 1990;57:227-34.
59. Dalaker K, Smith P, Arnesen H, Prydz H. Factor VII-phospholipid complex in male survivors of acute myocardial infarction. Acta Med Scand 1987;222:111-6.
60. Broadhurst P, Kelleher C, Hughes L, et al. Fibrinogen, factor VII clotting activity, and coronary artery disease severity. Atherosclerosis 1990;85:169-73.
61. Meade TW, North WRS, Chakrharti R, et al. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1980;1:1050-4.
62. Cortellaro M, Boschetti C, Confrancesco E, et al. The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Arterioscler Thromb 1992;12:1063-70.
63. Meade TW, Vickers MV, Thompson SG, et al. Epidemiological characteristics of platelet aggregability. Br Med J 1985;290:428-32.
64. Colwell JA, Sagel J, Crook L, Chambers A, Laimins M. Correlation of platelet aggregation, plasma factor activity, and megathrombocytes in diabetic subjects with and without vascular disease. Metabolism 1977;26:279-85.
65. Bierenbaum ML, Fleischman AI, Stier A, Somol H, Watson PB. Effect of cigarette smoking upon in vivo platelet function in men. Thromb Res 1978;12:1051-7.
66. Glynn MF, Mustard JF, Buchanan MR, Murphy EA. Cigarette smoking and platelet aggregation. Can Med Assoc J 1966;95:549-53.
67. Carvalho AC, Colman RW, Lees RS. Platelet function in hyperlipoproteinemia. N Engl J Med 1974;290:434-8.
68. Tofler GH, Brezinski D, Schafer AI, et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med 1987;316:1514-8.
69. Renaud S, Dumont E, Godsey F, Suplisson A, Thevenon C. Platelet functions in relation to dietary fats in farmers from two regions of France. Thromb Haemost 1978;40:518-31.
70. Renaud S, Dumont E, Godsey F. Dietary fats and platelet factors in French and Scottish farmers. Nutr Metab 1980;24(supp 1):90-104.
71. Renaud S, Morazain R, Godsey F, et al. Platelet functions in relation to diet and serum lipids in British farmers. Br Heart J 1981;46:562-70.
72. Renaud S, Godsey F, Dumont E, et al. Influence of long-term diet modification on platelet function and composition in Moselle farmers. Am J Clin Nutr 1986;43:136-50.
73. Zahavi J, Dreyfuss F. An abnormal pattern of adenosine diphosphate-induced platelet aggregation in acute myocardial infarction. Thromb Diath Haemorrh 1969;21:76-88.
74. Sjogren A, Bottiger LE, Biorck G, Wahlberg F, Carlson LA. Adenosine-diphosphate-induced platelet adhesiveness in patients with ischaemic heart disease. Acta Med Scand 1970;187:89-94.
75. Goldenfarb PB, Cathey MH, Zucker S, Wilber P, Corrigan JJ Jr. Changes in the hemostatic mechanism after myocardial infarction. Circulation 1971;43:538-46.
76. Salky N, Dugdale M. Platelet abnormalities in ischemic heart disease. Am J Cardiol 1973;32:612-7.
77. Gormsen J, Nielsen JD, Dalsgaard J, et al. ADP-induced platelet aggregation in vitro in patients with ischemic heart disease and peripheral thromboatherosclerosis. Acta Med Scand 1977;201:509-13.
78. Sorkin RP, Tokarsky JM, Huber-Smith MJ, Steiger JF, McCann DS. In vivo platelet aggregation and plasma catecholamines in acute myocardial infarction. Am Heart J 1982;104:1255-61.
79. Wu KK, Hoak JC. Increased platelet aggregates in patients with transient ischemic attacks. Stroke 1975;6:521-4.
80. Lou HC, Nielsen JD, Bomholt A, Gormsen J. Platelet hyperaggregability in young patients with completed stroke. Acta Neurol Scand 1977;56:326-34.
81. Andersen LA, Gormsen J. Platelet aggregation and fibrinolytic activity in transient cerebral ischemia. Acta Neurol Scand 1976;55:76-82.
82. Warlow CP, Rennie JA, Ogston D, Douglas AS. Platelet adhesiveness and fibrinolysis after recent cerebrovascular accidents and their relationship with subsequent deep venous thrombosis of the legs. Thromb Haemost 1976;36:127-32.
83. Rubenfire M, Blevins RD, Barnhart M. Platelet hyperaggregability in patients with chest pain and angiographically normal coronary arteries. Am J Cardiol 1986;57:657-60.
84. Elwood PC, Renaud S, Sharp DS. Ischemic heart disease and platelet aggregation. The Caerphilly Collaborative Heart Disease Study. Circulation 1991;83:38-44.
85. Trip MD, Cats VM, VanCapelle FJL, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990;322:1549-54.
86. Eaton DL, Fless GM, Kohr WJ, et al. Partial amino acid sequence of apo lipoprotein (a) shows that it is homologous to plasminogen. Proc Natl Acad Sci U S A 1987;84:3224-8.
87. McLean JW, Tomlinson JE, Kuang W-J, et al. cDNA sequence of human apo lipoprotein (a) is homologous to plasminogen. Nature 1987;330:132-7.
88. Hajjar K, Gavish D, Breslow JL, Nachman RL. Lipoprotein (a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989;339:303-5.
89. Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein (a), fibrin binding, and plasminogen activation. Arteriosclerosis 1990;10:240-5.
90. Haberland ME, Fless GM, Scanu AM, Fogelman AM. Malondialdehyde modification of lipoprotein (a) produces acid uptake of human monocytemacrophages. J Biol Chem 1992;267:4143-51.
91. Terres W, Tatsis E, Pfalzer B, et al. Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein (a). Circulation 1995;91:948-50.
92. Scanu AM, Fless GM. Lipoprotein (a). Heterogeneity and biological relevance. J Clin Invest 1990;85:1709-15.
93. Eliasson M, Evrin P-E, Lundblad D. Fibrinogen and fibrinolytic variables in relation to anthropometry, lipids, and blood pressure. The Northern Sweden MONICA study. J Clin Epidemiol 1994;47:513-24.
94. Landin K, Stigendal L, Eriksson E. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 1990;39:1044-8.
95. Vague P, Juhan-Vague I, Aillaud MF. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 1986;35:250-3.
96. Folsom AR, Qamhieh HT, Wing RR. Impact of weight loss on plasminogen activator inhibitor (PAI-1). factor VII, and other hemostatic factors in moderately overweight adults. Arterioscler Thromb 1993;13:162-9.
97. Sakata K, Kurata C, Kobayashi A, Rydzewski A, Yamazaki N. Plasminogen activator inhibitor activity as a possible indicator of disease activity in rest angina with angiographically insignificant coronary artery stenosis. Thromb Res 1991;63:491-502.
98. Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985;313:1557-63.
99. Gray RP, Patterson DL, Yudkin JS. Plasminogen activator inhibitor activity in diabetic and non-diabetic survivors of myocardial infarction. Arterioscler Thromb 1993;13:415-20.
100. Hamsten A, deFaire U, Walldius G. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987;2:3-9.
101. Meade TW, Chakrabarti R, Haines AP, North WR, Stirling Y. Characteristics affecting fibrinolytic activity and plasma fibrinogen concentrations. Br Med J 1979;1:153-6.
102. Szymanski LM, Pate RR. Fibrinolytic responses to moderate intensity exercise. Comparison of physically active and inactive men. Arteriocler Thromb 1994;14:1746-50.
103. Jansson JH, Nilsson TK, Olofsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 1991;12:157-61.
104. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue activator mass concentration on long-term mortality in patients with coronary artery disease: a seven-year follow up. Circulation 1993; 88:2030-4.